Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase EARLY_PHASE1 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Gynecologic 1Gastrointestinal 1

Conditions

Ovarian Neoplasms 1Mesothelioma 1Carcinoma, Pancreatic Ductal 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 5fludarabine 4Specimen Handling 3alpha-Synuclein 2Magnetic Resonance Spectroscopy 2Interleukin-2 2theanine 1temsirolimus 1spartalizumab 1sodium thiosulfate 1selicrelumab 1perflutren 1malic acid 1amatuximab 1X-Rays 1Valproic Acid 1Topotecan 1Surgical Procedures, Operative 1Sunitinib 1Sulfur Hexafluoride 1Sirolimus 1Resistant Starch 1Radiotherapy 1Radiation 1Platinum 1Paclitaxel 1Liquid Biopsy 1KD025 1Interviews as Topic 1Indocyanine Green 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × amatuximab × Other solid neoplasm × Clear all
NCT01413451 2019-12-17

Amatuximab for High Mesothelin Cancers

National Institutes of Health Clinical Center (CC)

Phase EARLY_PHASE1 Terminated
7 enrolled
GastrointestinalGynecologicOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Carcinoma, Pancreatic Ductal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡